Insider Transactions in Q4 2025 at Veracyte, Inc. (VCYT)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
10,739
-6.85%
|
$461,777
$43.41 P/Share
|
|
Dec 05
2025
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
20,000
-23.93%
|
$900,000
$45.65 P/Share
|
|
Dec 05
2025
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+26.38%
|
$140,000
$7.77 P/Share
|
|
Dec 04
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
1,278
-1.53%
|
$60,066
$47.51 P/Share
|
|
Dec 04
2025
|
Marc Stapley Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,668
-1.18%
|
$360,396
$47.13 P/Share
|
|
Dec 04
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,278
-5.55%
|
$610,788
$46.93 P/Share
|
|
Dec 04
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,422
-0.89%
|
$66,834
$47.3 P/Share
|
|
Dec 02
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,325
-3.42%
|
$60,950
$46.16 P/Share
|
|
Dec 02
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
2,900
-3.36%
|
$133,400
$46.16 P/Share
|
|
Dec 02
2025
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,914
-2.37%
|
$364,044
$46.16 P/Share
|
|
Dec 02
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,384
-2.68%
|
$155,664
$46.16 P/Share
|
|
Dec 02
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,052
-3.68%
|
$140,392
$46.16 P/Share
|
|
Dec 02
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,955
-3.2%
|
$135,930
$46.16 P/Share
|
|
Nov 25
2025
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
1,106
-3.63%
|
$55,300
$50.25 P/Share
|
|
Nov 25
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
2,808
-3.15%
|
$140,400
$50.0 P/Share
|
|
Nov 20
2025
|
Jens Holstein Director |
SELL
Open market or private sale
|
Direct |
10,000
-9.61%
|
$420,000
$42.21 P/Share
|
|
Nov 10
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,102
-11.64%
|
$214,284
$42.33 P/Share
|
|
Nov 07
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,818
-11.71%
|
$232,720
$40.21 P/Share
|
|
Nov 05
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,000
-5.26%
|
$287,000
$41.0 P/Share
|
|
Nov 05
2025
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
9,674
-41.65%
|
$386,960
$40.02 P/Share
|
|
Nov 05
2025
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
43,196
-12.11%
|
$1,900,624
$44.29 P/Share
|
|
Nov 05
2025
|
Evan/ Fa Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+13.75%
|
$180,000
$6.94 P/Share
|
|
Nov 05
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,466
-7.23%
|
$258,640
$40.0 P/Share
|
|
Oct 28
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,886
+5.49%
|
-
|
|
Oct 06
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
8,349
-8.28%
|
$300,564
$36.02 P/Share
|
|
Oct 01
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,160
-2.36%
|
$75,600
$35.0 P/Share
|
|
Oct 01
2025
|
Robert S Epstein Director |
SELL
Open market or private sale
|
Direct |
21,473
-25.59%
|
$751,555
$35.08 P/Share
|
|
Oct 01
2025
|
Robert S Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+10.65%
|
$70,000
$7.94 P/Share
|
|
Oct 01
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
2,539
-2.77%
|
$88,865
$35.0 P/Share
|